Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Rijavec E, Genova C, Barletta G, Biello F, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Boccardo F, Grossi F. Rijavec E, et al. Among authors: truini a. Expert Opin Pharmacother. 2014 Aug;15(12):1771-80. doi: 10.1517/14656566.2014.938639. Expert Opin Pharmacother. 2014. PMID: 25032887 Review.
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
Dal Bello MG, Alama A, Barletta G, Coco S, Truini A, Vanni I, Boccardo S, Genova C, Rijavec E, Biello F, Bottoni G, Sambuceti G, Grossi F. Dal Bello MG, et al. Among authors: truini a. Int J Cancer. 2015 Dec 15;137(12):2947-58. doi: 10.1002/ijc.29647. Epub 2015 Jul 15. Int J Cancer. 2015. PMID: 26089022 Free article.
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition.
Coco S, Truini A, Alama A, Dal Bello MG, Venè R, Garuti A, Carminati E, Rijavec E, Genova C, Barletta G, Sini C, Ballestrero A, Boccardo F, Grossi F. Coco S, et al. Among authors: truini a. Target Oncol. 2015 Sep;10(3):393-404. doi: 10.1007/s11523-014-0344-7. Epub 2014 Oct 25. Target Oncol. 2015. PMID: 25341405
Belagenpumatucel-L for the treatment of non-small cell lung cancer.
Rijavec E, Biello F, Genova C, Barletta G, Maggioni C, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Beltramini S, Grassi MA, Boccardo F, Grossi F. Rijavec E, et al. Among authors: truini a. Expert Opin Biol Ther. 2015;15(9):1371-9. doi: 10.1517/14712598.2015.1073709. Epub 2015 Jul 27. Expert Opin Biol Ther. 2015. PMID: 26211534 Review.
Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S, Alama A, Vanni I, Fontana V, Genova C, Dal Bello MG, Truini A, Rijavec E, Biello F, Sini C, Burrafato G, Maggioni C, Barletta G, Grossi F. Coco S, et al. Among authors: truini a. Int J Mol Sci. 2017 May 11;18(5):1035. doi: 10.3390/ijms18051035. Int J Mol Sci. 2017. PMID: 28492516 Free PMC article.
Pemetrexed for the treatment of non-small cell lung cancer.
Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G, Dal Bello MG, Alama A, Savarino G, Pronzato P, Boccardo F, Grossi F. Genova C, et al. Among authors: truini a. Expert Opin Pharmacother. 2013 Aug;14(11):1545-58. doi: 10.1517/14656566.2013.802774. Epub 2013 May 17. Expert Opin Pharmacother. 2013. PMID: 23683110 Review.
Afatinib for the treatment of advanced non-small-cell lung cancer.
Genova C, Rijavec E, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, Grossi F. Genova C, et al. Among authors: truini a. Expert Opin Pharmacother. 2014 Apr;15(6):889-903. doi: 10.1517/14656566.2014.902445. Expert Opin Pharmacother. 2014. PMID: 24646054 Review.
220 results